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Protein-protein interactions (PPIs) underlie the majority of biological processes, signaling, and disease.
Approaches to modulate PPIs with small molecules have therefore attracted increasing interest over the
past decade. However, there are a number of challenges inherent in developing small-molecule PPI inhibitors
that have prevented these approaches from reaching their full potential. From target validation to small-mole-
cule screening and lead optimization, identifying therapeutically relevant PPIs that can be successfully
modulated by small molecules is not a simple task. Following the recent review by Arkin et al., which sum-
marized the lessons learnt from prior successes, we focus in this article on the specific challenges of devel-
oping PPI inhibitors and detail the recent advances in chemistry, biology, and computation that facilitate
overcoming them. We conclude by providing a perspective on the field and outlining four innovations that
we see as key enabling steps for successful development of small-molecule inhibitors targeting PPIs.Introduction
Protein-protein interactions (PPIs) have long been recognized as
the key regulators of cellular pathways and networks. Developing
tools to probe these interactions has led to an increased under-
standing of biological systems, and PPIs have also been targeted
for drug development, due to the potential for selectively inter-
fering with specific cellular pathways (Higueruelo et al., 2013;
Mullard, 2012; Wells and McClendon, 2007). Indeed, several
small-molecule modulators of PPIs are already in clinical use,
while others are currently being evaluated in clinical trials (Table
1). A recent review focused on the properties of PPI inhibitors re-
garded as clinical success stories and discussed their specific
mechanisms of action (Arkin et al., 2014). PPI inhibitors were
separated into the classes of primary, secondary, and tertiary
structural epitopes, as well as allosteric modulators. The future
prospects for PPI-targeted drug discovery and the likelihood of
success was discussed in each case. However, despite the
notable successes, there have been many failures in identifying
PPI inhibitors, and it is clear that inhibiting PPIs with small mole-
cules remains a major challenge (Morelli et al., 2011; Villoutreix
et al., 2014; Zinzalla and Thurston, 2009). In this review, we detail
the specific chemical and biological challenges associated with
inhibiting PPIs using small molecules, as well as the competitive
advantages. We then discuss novel experimental and computa-
tional approaches to developing PPI inhibitors, with illustrative
examples. A key point that we address concerns insights into
the molecular basis for the reduced druggability of PPIs, in terms
of howprotein surfaces interactwith smallmolecules. To focuson
current approaches, we have chosen to cite recent applications
of each approach rather than earlier work in their development.
Although most approved PPI inhibitors currently find applica-
tion as treatments for cancer or in regulation of the immune sys-Chemistry & Bitem, therapeutics targeting infectious diseases such as HIV have
also been approved. With a greater understanding of the cellular
pathways indifferentorganismswill comean increase in theability
of PPI inhibitors to target infectious diseases. At the same time,
the availability of patient-specific and tumor-specific data from
high-throughput genome sequencing will enhance the potential
of PPI inhibitors for targeting cancer. Prior to the early 1990s,
PPI inhibitors were primarily identified through phenotypic
screening, consistent with drug discovery approaches at the
time. From the more recent examples, it is interesting to note
that clinical candidates were originally identified using a wide va-
riety of different in vitro approaches, including radioligandbinding
assays, fluorescence-based assays, fragment-based drug dis-
covery (FBDD), and peptide mimic approaches. This observation
suggests that PPI drug targets should be approached using
several experimental methods, to maximize the probability of
finding promising small-molecule leads. Exploiting multiple ap-
proaches is important because different kinds of PPI exhibit
significantly different structural characteristics and present
different challenges. For example, inhibitors required to mimic
linear protein sequences (such as integrin inhibitors) have proved
moresuccessful than inhibitors required tomimicsingle regionsof
secondary structure (suchasa-helixorb-hairpinmimics),which in
turn have proved more successful than inhibitors required to
mimic discontinuous binding epitopes derived from tertiary struc-
tures (Arkin et al., 2014). In addition to small molecules, there has
been great interest in the use of biologics to target PPIs. It is our
opinion that, in the majority of cases, extracellular targets are
best approached with biologics such as antibodies or protein
drugs. In contrast, biologics are inherently less suitable for intra-
cellular targets in the current state of the art, necessitating the
use of small molecules. While the use of biologics to target PPIsology 22, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 689
Table 1. Examples of Small-Molecule PPI Modulators in Clinical Use or Currently Undergoing Clinical Trials, Including their Mode of
Action, Identification Method, and Clinical Status
Name Structure Mode of Action Identification Method Clinical Status
Colchicine
(Ahern et al., 1987)
microtubule
polymerization
inhibitor
phenotypic screen approved for gout
Vinblastine
(Noble et al., 1977)
microtubule
polymerization
inhibitor
phenotypic screen approved for several
carcinomas
SAR1118
(Zhong et al., 2012)
LFA-1/ICAM-1
inhibitor
peptide mimic phase III for
dry eye
Navitoclax (ABT-263)
(Tse et al., 2008)
Bcl-2/Bcl-XL inhibitor fragment screen phase II cancer
RG7112 (Vu et al., 2013) p53/MDM2
inhibitor
in vitro assay phase Ib cancer
BI224436
(Fader et al., 2014)
LEDGF/integrase
inhibitor
in vitro assay phase I HIV
LFA-1, lymphocyte function associated antigen 1; ICAM-1, intercellular adhesion molecule 1; Bcl-2, B-cell lymphoma 2; MDM2, mouse double minute
2; LEDGF, lens epithelium derived growth factor.
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viewtosmallmolecules,peptides,andpeptidemimics.Fora thor-
oughdiscussion on the subject of biologics, we refer the reader to
other reviews (Leaderet al., 2008;Sathishet al., 2013).However, it
is worth nothing that many of the advantages and many of the
challenges relevant to developing small-molecule inhibitors of
PPIs are also relevant to the development of biologics.690 Chemistry & Biology 22, June 18, 2015 ª2015 Elsevier Ltd All rigPPI Inhibitors as Next-Generation Therapeutics
Expanding the Druggable Genome
The pharmaceutical industry has successfully developed drugs
targeting only a small fraction of the components in the cellular
signaling pathways that are misregulated in disease. Recent
analysis of drug discovery efforts reveals that of the 15,000–
20,000 genes encoded by the human genome, less than 300hts reserved
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et al., 2006). More importantly, approximately two-thirds of these
are directed against only ten classes of target, which comprise
the so-called druggable genome. This analysis suggests that
the size of the classically druggable genome is likely to be around
1,500 proteins at best. Expanding the druggable genome by ac-
cessing new target classes is therefore of the utmost importance
in order to deliver improved health care. An accepted route to ex-
panding this target repertoire is to generate molecules that
inhibit the physical interaction of biological macromolecules
(Archakov et al., 2003; Fry, 2006; Ruffner et al., 2007; Wells
and McClendon, 2007). All cellular pathways are characterized
by the physical interaction of biological macromolecules, most
notably PPIs. Developing the technology required to find small-
molecule inhibitors of PPIs represents a significant step toward
expanding the druggable genome.
Increased Selectivity
Compared with the highly conserved nature of substrate bind-
ing pockets in enzyme classes such as kinases, PPI interfaces
are inherently more diverse. For this reason, commentators
have long postulated that PPI inhibitors will offer increased
selectivity compared with existing small molecules. Maximizing
target selectivity, of course, reduces the likelihood of off-target
toxicities. In the well-publicized case of ATP-competitive kinase
inhibitors, it is now an essential component of any assay
cascade to rapidly ascertain the level of selectivity at target
compared with the remainder of the kinome, by comparison
against a panel of kinases (Davis et al., 2011). While multi-ki-
nase inhibitors have shown clinical utility in some oncology set-
tings (Rhodes et al., 2008), the need to reduce dose-limiting
toxicities by increasing selectivity is a central driver for all
drug discovery projects. For what reasons are PPI inhibitors
likely to be more selective than their substrate-competitive
counterparts? Perhaps the single most important reason is
that the large surface area of a typical PPI interface offers
more room to encode selectivity compared with the physically
constrained environment of a substrate binding site. Incorpo-
rated within this concept is the fact that the chemical nature
of substrate binding sites are defined absolutely by an invariant
small molecule, while PPI interfaces have co-evolved together
unhindered by a locked chemical structure, and, by definition,
are therefore more diverse. At present, there is currently no
PPI equivalent of a ‘‘kinase selectivity panel’’ other than the
cell itself, and with only a small number of PPI inhibitors having
made it to the clinic thus far, it is too early to draw any data-
driven conclusions regarding this selectivity issue. However,
the use of stapled a-helical peptides (see the section on Pep-
tides and Peptide Mimics) provides encouraging preliminary
data that selectivity at PPI interfaces is indeed achievable.
Although still in its infancy, this approach has already generated
numerous a-helical peptides that show clear target engage-
ment and mechanism-dependent phenotypic responses in
cell-based assays, and, more importantly, are tolerable and effi-
cacious in in vivo models (Moellering et al., 2009). The impor-
tance of this observation lies in the fact that around 30% of
all protein secondary structure is a-helical (Azzarito et al.,
2013) and that, even with this limited template, specificity is
achieved in the cell in order to drive orchestrated signaling
pathways.Chemistry & BiReduced Susceptibility to Resistance Mutations
Clinical resistance to substrate-competitive enzyme inhibitors
occurs through the selection of mutant enzymes in which inhib-
itor binding is prevented by the alteration of non-essential struc-
tural features that contribute to binding affinity, without affecting
the ability of the enzyme to bind to its natural substrate. In
contrast to the evolutionary conservation of enzyme active sites,
the structural features that underlie PPIs are often quite distinct,
even between closely related enzymes, in enabling their specific
cellular functions. These diverse structural features would seem
likely to make resistance mutations that decrease inhibitor bind-
ing without perturbing the natural substrate less frequent. There-
fore, in principle, targeting the PPIs that underlie protein function
offers an attractive alternative to active-site inhibition of en-
zymes. Combining ATP-competitive kinase inhibitors with allo-
steric inhibitors of the same target to stall or even prevent the
emergence of resistance is a novel concept in cancer drug dis-
covery. Recent studies from Novartis have supported this
concept, at least in a pre-clinical setting (Adria´n et al., 2006;
Zhang et al., 2010). In these studies, the combination of the
ATP-competitive Bcr-Abl inhibitor imatinib with an allosteric in-
hibitor, GNF-5, suppressed the emergence of resistance in cell
culture experiments, and showed additive efficacy in an in vivo
model of bone marrow transplantation. In cases where resis-
tance mutations do occur, strategies to diminish their effect
can be applied. These include machine-learning techniques,
which have been applied to designing antimicrobial peptides
(Fjell et al., 2009), and the substrate envelope hypothesis,
whereby small-molecule inhibitors designed to mimic the shape
of the natural substrates do not to lead to the development of
resistance mutations (Parai et al., 2012).
Generating Novel Chemical Probes
In addition to widening the druggable genome and providing a
wealth of new therapeutic targets, inhibitors of PPIs may also
be useful chemical tools to probe cellular networks. Compared
with small interfering RNA knockdown, they offer the potential
of inhibiting a specific protein function without completely
removing the protein from the cell. Several academic drug dis-
covery platforms such as the NIH Molecular Libraries Program
and the Structural Genomics Consortium (SGC) have made opti-
mized compounds publicly available as probe compounds. In
the case of the SGC, these follow stringent criteria making
them suitable for effectively studying protein function: on-target
potency must be better than 100 nM, selectivity must be at least
30-fold, while cellular potency must be better than 1 mM (http://
www.thesgc.org/chemical-probes). Among these reported
probes, PPI modulators of the BET bromodomains have been
used to study their biological function and potential as anti-can-
cer therapeutics (Filippakopoulos et al., 2010).
Scope to Tailor Physical Properties
PPI inhibitors will by nature tend to be more solvent exposed
than traditional active-site inhibitors because they bind at pro-
tein surfaces. While this is a disadvantage in terms of ligand
efficiency (LE), it can be an advantage in terms of pharmacoki-
netic/pharmacodynamic (PK/PD) control. An inhibitor that is
buried in a binding site is likely to have the majority of its surface
in close contact with the protein and, thus, very little of its sur-
face available for chemical elaboration. Conversely, a PPI inhib-
itor that is half exposed to solvent has a much greater scope forology 22, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 691
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as the octanol/water partition coefficient (LogP) and polar sur-
face area to be tailored without adversely affecting the binding
affinity. This scenario has been exploited by Abbott for the
development of Bcl-2 inhibitors in the progression from ABT-
737 to ABT-263, where solvent-exposed positions were modi-
fied to optimize the balance between oral exposure in animals
and efficacy in human tumor cell lines (Tse et al., 2008). A
similar approach was adopted during the optimization of the
MDM2/p53-inhibiting compounds, the Nutlins, to yield
RG7112, an inhibitor now in human clinical trials (Vu et al.,
2013). Increased solvent exposure of an inhibitor in complex
also leads to more natural sites for synthetic coupling with
cell-trafficking moieties such as peptides and sugars, in addi-
tion to other species appropriate for pro-drug strategies
(Gynther et al., 2008, 2009).
Major Challenges of Developing PPI Inhibitors
Identifying Therapeutically Relevant PPIs
Therapeutic targets are either established on a case-by-case ba-
sis as a result of focused research efforts, often within academia,
or are identified using unbiased screens that attempt to asso-
ciate particular gene products with a specific cellular response
or phenotype. In terms of focused research, recent efforts
have been guided by studying PPI networks. Understanding
such networks would allow for major advances in biology such
as identifying synthetic lethal interactions, understanding modes
of toxicity, and explaining the resilience of cellular networks to
disruption (Hopkins, 2008); these are all important factors in
drug discovery. In particular there has been a focus on under-
standing the role of hub proteins in cellular networks (Batada
et al., 2006) and exploring their potential as drug targets (Hop-
kins, 2008). Computational work in this area holds much promise
(Hood and Perlmutter, 2004; Yildirim et al., 2007), but the
complexity of biological systems and the need to integrate
diverse data and different methods means that successful appli-
cation of systems biology to target selection remains a goal for
the future.
RNAi has proved to be a successful tool for identifying new
therapeutic targets that fall within the definition of classical
drug targets, such as kinases, for both focused and unbiased
approaches. However RNAi has, thus far, failed to expand the
‘‘druggable genome’’ beyond established target classes. This
limitation can be explained simply by the fact that disruption
of macromolecular assemblies by the loss of a single protein
component is likely to lead to a confounded phenotypic effect,
which is not directly attributable to the loss of that particular
protein but to the perturbation of a higher-order macromolec-
ular structure. In order to identify novel and therapeutically
relevant PPIs, we propose that a different suite of target identi-
fication tools will be required. The most intuitive method for dis-
rupting PPIs is to use ectopically expressed peptides to act in
the manner of dominant negatives, thereby inhibiting PPIs.
Screens of this type have been approached in a number of
ways. In their simplest form, random peptide libraries can be
generated and expressed in a mammalian cell line, and
deflection from the intended phenotype measured using an
appropriate assay. However, screening using random peptide
libraries has been extensively investigated, and currently avail-692 Chemistry & Biology 22, June 18, 2015 ª2015 Elsevier Ltd All rigable methods suffer from low hit rates (as low as 1 in 106–107)
that often preclude further progression (Roepe, 2001; Xu
et al., 2001). New approaches addressing this problem remain
a major unmet need.
Challenges of Druggability
The concept of druggability measures the suitability of a protein
target or specific binding site for development of a small-mole-
cule inhibitor. It is important to note that studying binding to the
protein target in isolation does not consider PK/PD factors that
influence druggability. Thus, bindability (Sheridan et al., 2010) or
ligandability are perhaps better terms than druggability, but
druggability tends to be the common parlance. The most
obvious difficulty in targeting PPIs for drug development is the
reduced druggability of protein surfaces in comparison with
buried active sites, which have evolved to bind small molecules
(Wells and McClendon, 2007). For example, in the work by Haj-
duk et al. (2005) on protein druggability of different protein clas-
ses derived from receptor-based nuclear magnetic resonance
(NMR) screening of a fragment library, the protein binding tar-
gets are at the lower end of the druggability spectrum. Of the
PPIs screened, only 30% were identified as containing a drug-
gable binding site. This compares with the traditionally drug-
gable protein kinases (45%), oxidoreductases (60%), and lyases
(75%). In another study, druggability was correlated with
compact pockets and rough surfaces, rather than the large
and flat interfaces typically associated with PPIs (Wells and
McClendon, 2007). The interaction energy between a ligand
and a protein is derived from close contact between the two
partners. In a buried binding site the protein surface can contact
100% of the ligand surface, whereas the interface may contact
50% or less of the ligand surface at a solvent-exposed protein
surface. Thus, the inherent challenge in developing molecules
that bind strongly to flat surfaces is the difficulty in achieving suf-
ficient contact to yield the required interaction energy. For this
reason, the expectation is that PPI inhibitors will need to be
larger on average than traditional inhibitors to reach the same
levels of potency. This assertion is supported by data from a
number of studies (Higueruelo et al., 2009; Labbe´ et al., 2013;
Morelli et al., 2011). For example, the PPI inhibitors studied in
the TIMBAL database had a higher average molecular weight
than drug-like molecules bound to proteins in the PDB (420
versus 360) and, in addition to being heavier, they also had a
higher calculated octanol/water partition coefficient (cLogP)
(4.0 versus 2.6). In terms of drug development, it is known that
both molecular weight and lipophilicity are linked to poor
PK/PD properties (Johnson et al., 2009). It is also interesting to
consider the effect of these differences on the LE of PPI inhibi-
tors. LE is a measure of the average contribution of each heavy
atom to the binding affinity. It is commonly calculated from the
using the pIC50 (logarithmic half-maximal inhibitory concentra-
tion) the compound and the number of heavy atoms it contains
(HA), using Equation 1 (Hopkins et al., 2014).
LE=
1:373pIC50
HA
(Equation 1)
Lipophilic ligand efficiency (LLE) is another effective metric to
drive decision making in medicinal chemistry, due to the delete-
rious effects of high lipophilicity on outcomes in drug discovery.
LLE is calculated from the pIC50 of the compound and its cLogP,hts reserved
Figure 1. Distributions of Ligand Efficiency and Lipophilic Ligand
Efficiency
Bar graphs showing the distributions of (A) ligand efficiency (LE) and (B) lipo-
philic ligand efficiency (LLE) using IC50 data for 1,736 small molecules in the
TIMBAL database of PPI inhibitors and 37,143 small-molecule inhibitors in the
curated portion of the BindingDB database. Heavy atom counts and cLogP
values were computed using Schro¨dinger’s Qikprop, and the small molecules
were prepared using Schro¨dinger’s Ligprep.
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LiPE.
LLE=pIC50  cLogP (Equation 2)
Figure 1 presents LE and LLE data for PPI inhibitors in the
TIMBAL database and inhibitors in the BindingDB database
(Liu et al., 2007). Integrins have been removed from the TIMBAL
data due to difficulties in their curation. In addition, integrins are
generally considered to have more in common with traditional
drug targets than with PPI targets, as they tend to bind very short
peptide motifs with high affinity. The results for the integrins are
presented in Figure S1. The average LE for the PPI inhibitors
studied was 0.23 kcal/mol per heavy atom, compared with an
average of 0.32 kcal/mol per heavy atom for inhibitors in the
BindingDB. The average LLE for the PPI inhibitors studied was
1.32, compared with an average of 3.12 for inhibitors in the Bind-
ingDB. As a guide the respective mean LE and LLE of oral drugs
have been calculated as 0.45 kcal/mol per heavy atom and 4.43
(Gleeson et al., 2011; Hopkins et al., 2014), and it has been sug-
gested that drug candidates should have an LE of greater thanChemistry & Bi0.30 kcal/mol per heavy atom (Hajduk, 2006; Hopkins et al.,
2004) and an LLE of greater than 5.00 (Leeson and Springthorpe,
2007). Only 14.5% of the molecules in TIMBAL pass this LE filter
and only 4.5% pass the LLE filter. Conversely, 54.8% of the mol-
ecules in the BindingDB pass the LE filter and 17.4% pass the
LLE filter. In good agreement with this work, previous studies
have calculated the average LE as 0.24 kcal/mol per heavy
atom (Wells and McClendon, 2007) or 0.27 kcal/mol per heavy
atom for PPI inhibitors and 0.32 kcal/mol per heavy atom for
typical medicinal chemistry leads (Higueruelo et al., 2009).
Based on these studies, a PPI inhibitor with 30 heavy atoms is
expected to have a binding affinity of 1 mM, versus 90 nM for
the typical medicinal chemistry lead (Hopkins et al., 2004). To
reach 90 nM potency, the molecular weight of the PPI inhibitor
would have to be increased by adding five to six heavy atoms.
It is important to note that adding atoms to a ligand has a ten-
dency to detrimentally affect its absorption, distribution, meta-
bolism, and excretion (ADME) profile. Thus, PPIs typically have
reduced druggability due to the inherent conflict between the
two key goals of maximizing surface contact area and optimizing
ADME properties. Reduced druggability will also have an impact
upon high-throughput screening (HTS), as there will on average
be fewer hits for a given library. This will lead to fewer alternative
chemotypes available for drug development, and in some cases
no viable hits. In particular, fragment screening against PPIs can
be especially challenging (Do¨mling, 2008), unless the target has
a strong binding hotspot or innovative strategies are applied (see
the section on Fragment Screening). To address this problem,
targeted small-molecule libraries for PPIs are now available,
containing larger and more complex molecules (see the section
on Customized HTS Libraries).
Structural Plasticity
While it is clear that PPIs can yield druggable targets, many of the
success stories involve proteins that undergo structural changes
upon binding (Aguirre et al., 2013). In general, these structural
changes at the binding interface tend to reveal more lipophilic
surfaces and pockets that complement lipophilic regions of the
binding partner. Such protein flexibility will confound traditional
structure-based approaches to target selection and lead optimi-
zation, because druggable pockets are not apparent in the apo
protein structures. For example, proteins such as MDM2 are
only predicted to be druggable when a liganded crystal structure
is used for the analysis (Cheng et al., 2007). Figure 2 illustrates
the extent of such structural changes in the case of six PPI inhib-
itors from the PDB (Berman et al., 2000). Figures 2A–2C illustrate
inhibitors of Bcl-XL, IL-2, and HDM2 overlaid on the protein
structure from the apo state. The changes in protein structure
mean that large portions of the inhibitors protrude into the pro-
tein surface. There are also cases, such as Keap1 (Figure 2D),
where modest changes at the protein surface can increase the
size of binding pockets and allow larger inhibitors than would
be expected from an analysis of the apo structure. While there
are cases where the apo and holo states are very similar, such
as HIV integrase (Figure 2E) and KRas (Figure 2F), these seem
to be in the minority. Six cases of proteins that undergo major
structural changes upon binding are also presented in the review
by Wells and McClendon (2007) on PPI inhibitors: IL-2, Bcl-XL,
HDM2, HPV11 3 102, ZipA, and TNF. The videos presented in
their supporting information illustrate the remarkable extent ofology 22, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 693
Figure 2. Apo Protein Structures of Six
Surfaces Involved in PPIs, Showing Clashes
with Ligands Overlaid from Protein-Ligand
Complex Structures
The apo and holo structures were aligned using
residues within 5.0 A˚ of the ligand, and the heavy
atom root-mean-square deviation (RMSD) of these
residues was calculated.
(A) Bcl-XL from PDB: 1R2D overlaid with the ligand
from PDB: 2O2N. The protein surface is shaded in
orange and the RMSD is 1.51 A˚.
(B) IL-2 from PDB: 1PY2 overlaid with the ligand
from PDB: 3INK. The protein surface is shaded in
cyan and the RMSD is 1.12 A˚.
(C) HDM2 from PDB: 1Z1M overlaid with the ligand
from PDB: 4IPF. The protein surface is shaded in
magenta and the RMSD is 1.49 A˚.
(D) Keap1 from PDB: 1ZGK overlaid with the ligand
from PDB: 4IFN. The protein surface is shaded in
yellow and the RMSD is 0.40 A˚.
(E) HIV integrase from PDB: 1EX4 overlaid with the
ligand from PDB: 4CE9. The protein surface is
shaded in purple and the RMSD is 0.76 A˚.
(F) KRas from PDB: 3GFT overlaid with the ligand
from PDB: 4EPY. The protein surface is shaded in
pink and the RMSD is 1.02 A˚. The ligands are dis-
played using CPK atom coloring in all cases.
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ner protein and the complex with the inhibitor.
Novel Experimental Tools for Targeting PPIs
Customized HTS Libraries
Interfaces between proteins are often large and lack a small-
molecule active site; therefore, it is no surprise that reported in-
hibitors are distinct from traditional drugs. Recent analyses have
shown that inhibitors of PPIs tend to be larger and more hydro-
phobic than traditional drugs or compounds found in current
screening collections (see the section on Challenges of Drugg-
ability). These observations have led several groups to define
rules to enrich screening collections for putative PPI inhibitors.
Re-evaluating guidelines is certainly a prudent choice, given
how poorly traditional compound collections have fared when
screened against PPIs (Fry et al., 2013). Computational ap-
proaches to do this have recently been presented, and several
new inhibitors of the p53/MDM2 interaction have been identified
(Koes et al., 2012; Reyne`s et al., 2010). Another interesting devel-
opment was the introduction of the ‘‘rule-of-four’’ (RO4), which
states that compounds should havemolecular weights of greater
than 400, cLogP values of greater than 4, more than four rings,
and more than four hydrogen-bond acceptors to deliver higher
hit rates for PPIs (Morelli et al., 2011). However, one must note
the increased risk of ADME failures in developing large, lipophilic
compounds (see the section on Challenges of Druggability). In
fact, recent data show that PPI inhibitors in clinical trials do not
have higher cLogP values compared with non-PPI inhibitors
despite having higher molecular weights (Kuenemann et al.,
2014). Despite these caveats, the RO4 has subsequently been
used to construct a PPI-focused library from commercially avail-
able compounds (Hamon et al., 2013). In addition to academic
groups, companies have adopted such rules and have designed
their own PPI-focused libraries. ChemDiv, Asinex, Comminex,694 Chemistry & Biology 22, June 18, 2015 ª2015 Elsevier Ltd All rigLife Chemicals, Otava Chemicals, and NQuix all have libraries
targeted at PPIs, which use both the RO4, decision trees, and
machine-learning methods (Neugebauer et al., 2007), among
other selection criteria (Hamon et al., 2013; Harris et al., 2011).
A set of commercially available libraries is detailed in Table 2.
Despite their promise, there are several more general limitations
to current approaches to library design for PPIs (Laraia and
Spring, 2013). The number of reported PPI inhibitors is relatively
low, and the number of successfully inhibited targets is even
lower; therefore, there are insufficient data for an accurate anal-
ysis to be conducted. In addition, very few PPI modulators have
been approved for clinical use, and those that have are mostly
natural products whose mechanism was only discovered
subsequently. Examples include rapamycin, cyclosporine, and
modulators of tubulin dynamics (Pommier and Marchand,
2012). Compounds used in the analyses are also heavily opti-
mized and originate from both fragment and HTS approaches,
and therefore do not necessarily reflect the requirements for an
initial lead. The concept of a ‘‘lead-like’’ library has been around
for many years (Teague et al., 1999), but a similar approach for
PPIs has yet to be fully validated. The difficulty lies in the fact
that PPIs are not a unified target class (like G-protein coupled re-
ceptors or kinases), which often contain structural similarities
that can be leveraged in library design. Therefore, small-mole-
cule inhibitors for different PPIs are unlikely to be similar to one
another, except in their ability to bind to the hydrophobic patches
at protein surfaces (Kuenemann et al., 2014). This would suggest
that screening libraries should be as diverse as possible to cater
for a variety of different PPIs (Huggins et al., 2011). The only
exception to this may be PPIs mediated by secondary protein
structures such as a helices (Whitby and Boger, 2012), which
are discussed separately in the section on Peptides and Peptide
Mimics. A validated approach for obtaining diverse screening
collections is diversity-oriented synthesis (Galloway et al.,hts reserved
Table 2. Commercial Libraries Targeted at PPIs
Supplier No. of Compounds Design Method Website
Otava Chemicals 1,330 decision trees http://www.otavachemicals.com/products/target-focused-
libraries/protein-protein-interaction
Otava Chemicals 1,020 similarity search http://www.otavachemicals.com/products/target-focused-
libraries/protein-protein-interaction
Otava Chemicals 520 b-turn mimetics http://www.otavachemicals.com/products/target-focused-
libraries/peptidomimetic
Asinex 7,000 shape analysis http://www.asinex.com/PPI_Library.html
ComInnex custom helix mimetics, macrocycles http://www.cominnex.com/focused_and_targeted_libraries
Life Chemicals 850 machine learning http://www.lifechemicals.com/services/targeted/general
Life Chemicals 23,200 2D fingerprint similarity http://www.lifechemicals.com/services/targeted/general
Life Chemicals 4,300 rule-of-four http://www.lifechemicals.com/services/targeted/general
NQuix NA NA http://nquix.com/screening-libraries
ChemDiv 125,000 peptidomimetics http://www.chemdiv.com/products/screening-libraries/
chemdivs-screening-libraries-list/
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diverse scaffolds as possible are synthesized efficiently in few
steps. Diversity is generally assessed using computational
methods, and several PPI inhibitors have been identified using
this approach (Marcaurelle et al., 2009). However, more research
is required to fully evaluate the potential of such libraries for the
identification of PPI inhibitors. With so many companies offering
targeted PPI libraries, it should only be a matter of time before
these approaches to library generation are validated or dis-
credited.
Assay Platforms for HTS
Screening methods for inhibiting PPIs vary depending on the
overall approach taken (Pagliaro et al., 2004). Different tech-
niques can be used for fragment screening (see the section on
Fragment Screening) rather than the more traditional HTS ap-
proaches (Winter et al., 2012). For HTS, the most simple and
widely used approach is the fluorescence polarization (FP) assay
(Arkin et al., 2004). This technique requires that one component
of the PPI can be truncated to a smaller peptide that still retains
affinity for the other protein. This peptide is then attached to a flu-
orophore, and the change in tumbling rate between bound and
unbound states forms the basis for the assay window. These as-
says are fast to run, amenable to 384- or even 1,536-well for-
mats, and require very little labeled peptide and protein. This
makes them ideal for HTS, which is why they have been used
on a wide scale. One of the downsides to this system is the
requirement for one of the two interacting proteins to be trun-
cated to a small (<40 amino acids) peptide. While FP is a suitable
technique for many PPIs, it may not be appropriate for PPIs with
extremely large binding interfaces or those with discontinuous
binding epitopes. In this case, ELISAs may offer an alternative,
as two full-length proteins can be used. However, the throughput
of ELISA assays is significantly lower. Other widely used assay
techniques include Fo¨rster Resonance Energy Transfer (FRET)
and AlphaScreen, both of which are extensively discussed else-
where (Arkin et al., 2004). An important issue with these high-
throughput assay techniques is the high rate of false positives,
which can occur as a result of fluorescent molecules that inter-
fere with the assay, as well as redox-active compounds or pro-Chemistry & Bitein-precipitating compounds. Ideally such compounds would
already be removed during the preparation of the screening li-
brary, and data-driven computational filters are already available
for this purpose (Baell and Holloway, 2010). However, if com-
pounds that do not pass these filters are included in screening
libraries, close attention must be paid to the results from
follow-up assays. Biophysical techniques (Dias and Ciulli,
2014; Pfaff et al., 2015) have been used for this purpose and
include NMR, surface plasmon resonance, and isothermal titra-
tion calorimetry. X-Ray crystallography offers a final validation of
binding and allows structure-based drug design. All recent suc-
cessful PPI projects have benefited from structural information,
as rearrangements in the protein upon small-molecule binding
are frequently observed (see the section on Structural Plasticity).
One could argue that traditional HTS, in addition to fragment
screening efforts against PPIs, would struggle enormously
without structural data.
Fragment Screening
FBDD has been adapted on a wide scale in the last 10–15 years.
One of the key advantages of this approach is the more efficient
coverage of chemical space by compounds of lower molecular
weight, requiring smaller screening libraries compared with
HTS. In the context of PPIs, numerous examples of inhibitors
have been identified using this approach (Abdel-Rahman et al.,
2011; Douse et al., 2015; Gao et al., 2014; Holvey et al., 2015;
Jose et al., 2012; Lund et al., 2015; Molzan et al., 2012; Moore
et al., 2009; Patrone et al., 2013; Van Molle et al., 2012; Yin
et al., 2014). Prominent examples include the Bcl-2 inhibitor
ABT-737 (Oltersdorf et al., 2005), inhibitors of the RAS oncogene
(Maurer et al., 2012), and inhibitors of the BET bromodomains
(Chung et al., 2012). As PPIs tend to stretch over a large surface
area but contain hotspots contributing a large proportion of the
binding energy, fragments would appear suitable to identify
these sites (Coyne et al., 2010; Scott et al., 2013; Valkov et al.,
2012). However, the risk of missing fragments whose binding af-
finity is beyond the limits of detection exists. This is more likely to
be the case in PPIs, where a fragment will cover a smaller area of
the overall binding interface. An interesting approach to partially
circumvent this problem is the use of tethering fragments (Wilsonology 22, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 695
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with protein thiols before engaging in non-covalent interactions.
This allows the adduct to be detected by mass spectrometry,
and was successfully used to identify an allosteric site to the
interleukin/interleukin-receptor binding interface (Braisted
et al., 2003). A criticism of the FBDD has been the lack of
three-dimensionality in the screening collections (Morley et al.,
2013). To address this issue, researchers at the Broad Institute
have implemented a diversity-oriented synthesis approach to
design sp3 and stereochemically rich fragments (Hung et al.,
2011). The resulting effect on rate and quality of hits will deter-
mine the utility of these compounds. In addition to providing
valuable hits for further elaboration, fragment screening has
gained traction as a tool to establish PPI druggability (Edfeldt
et al., 2011). It has been hypothesized that low hit rates in frag-
ment screens occur as a result of poor druggability, and that
therefore in such cases it may be wise to re-assess screening
programs of any kind for a given target or to select other ap-
proaches such as rational design. In summary, FBDD is a
welcome addition to the repertoire of techniques available for
identifying PPI modulators, and we believe that it complements
rather than replaces existing strategies such asHTS. If resources
are available and the target sufficiently validated, we would
advocate the use of such approaches in parallel to maximize
the chances of success.
Peptides and Peptide Mimics
Several research groups have shown that a large percentage of
PPIs are mediated by protein secondary structures. In particular,
a helices occur frequently on protein interfaces, and short a-he-
lical peptides based on the key binding hotspot may provide
suitable inhibitors of PPIs (Bullock et al., 2011). This enticing hy-
pothesis would suggest that every a-helix-containing PPI may
have a ‘‘ready-made’’ lead compound available. However, un-
modified peptides tend to be poor inhibitors due to the large
entropic penalty of binding to their target. Therefore, the search
for stabilized peptides and small molecules that mimic protein
secondary structure has recently been an active area of research
(Azzarito et al., 2013; Lao et al., 2014; Lee et al., 2011; Walensky
and Bird, 2014). Pioneering work by Grubbs, Verdine, Walensky,
and Sawyer on cyclizing alkene-containing peptides using ring-
closing metathesis has been shown to increase a helicity, po-
tency, and stability for select examples (Blackwell and Grubbs,
1998; Chang et al., 2013; Moellering et al., 2009). Aileron, a com-
pany founded to pursue this approach, has successfully
completed its first phase I clinical trial targeting growth hor-
mone-releasing hormone (Grigoryev, 2013). Other criticisms of
peptide therapeutics are the lack of cell permeability in the
absence of a specific targeting sequence and poor PK/PD prop-
erties. The success of the stapled peptide approach has been
the ability to obtain cell-permeable, active peptides without
tags and with improved PK/PD properties. However, this suc-
cess was achieved through trial and error rather than rational
design, because permeability and stability are very difficult to
calculate a priori. Thus, it is necessary to conduct extensive pep-
tide structure-activity relationships (SAR) to identify suitable can-
didates. Despite this, stapled or cyclic peptides remain an
exciting approach to tackle PPIs, especially if one considers
that several naturally occurring cyclic peptides are already
approved drugs with acceptable properties (Liskamp et al.,696 Chemistry & Biology 22, June 18, 2015 ª2015 Elsevier Ltd All rig2008). Different methods of cyclization and stabilization have
now been reported, providing a wealth of options to those at-
tempting this approach (Lau et al., 2014).
In addition to stabilized peptides, small-molecule scaffolds
that mimic protein secondary structure have been reported by
several groups. Pioneering work by Hamilton identified the ter-
phenyl scaffold as an a-helix surrogate (Cummings and Hamil-
ton, 2010). Second-generation scaffolds that possess improved
solubility and synthetic tractability have been identified (Shagi-
nian et al., 2009). Of particular note is the work by the Wilson
group on the solid-phase synthesis of oligo-amides (Murphy
et al., 2013). This mimic can now be assembled rapidly with sim-
ple preparation and purification methods, and different building
blocks are now available for every amino acid. Despite promising
work in the field, potent inhibitors derived from this approach
have yet to be published, and it seems increasingly unlikely
that a singular scaffold will be applicable to all a-helix-mediated
PPIs. However, it continues to be a fruitful approach for discov-
ering probe compounds, and further developments may provide
compounds for clinical testing.
Novel Computational Tools for Targeting PPIs
In this sectionwe discuss the computational tools that have been
used to facilitate and understand PPIs and to aid in the discovery
of inhibitors. A number of the computational techniques dis-
cussed in this article are described in Table S1, along with refer-
ences to available software and theory papers.
Predicting PPI Interfaces
Studying a PPI as a potential therapeutic target first requires
identification and characterization of the binding interface. A
number of computational methods have been used to identify
PPI interfaces from protein structures (Ferna´ndez-Recio, 2011;
Fuller et al., 2009). Computational predictions based on a
consensus neural network method were found to yield 80% pre-
diction accuracy with 51% coverage on a set of 100 non-homol-
ogous protein chains taken from PPI complexes (Chen and
Zhou, 2005). Statistical methods based on residue pair fre-
quencies (Negi and Braun, 2007), frequencies of short polypep-
tide sequences (Pitre et al., 2006), and probabilistic analysis of
orthogonal protein features show similar predictive power (Scott
and Barton, 2007). Methods based on the similarity of interface
regions have also been successfully employed to predict the
structure of binding interfaces, but require a template in the
reference dataset to achieve this (Tuncbag et al., 2012). How-
ever, due to the effect of protein flexibility discussed above, it
is easier to identify a binding interface from a separated PPI
complex, and a generally applicable method should be able to
identify the binding interface from protein structures in their
separated structures. It is interesting to note that the abilities of
numerous methods to achieve this task have been indepen-
dently assessed by CAPRI (Critical Assessment of PRedicted
Interactions), an ongoing experiment to assess the ability of pro-
tein-docking methods to predict PPIs. Through 9 years and four
rounds of testing on 42 test cases, the conclusion is that current
methods yield reasonably accurate models, but only in the
absence of major conformational changes (Janin, 2010). In addi-
tion to identifying binding interfaces, it would be very useful to
have the power to identify potential allosteric binding sites that
modulate PPIs (Freire, 2000). While efforts have been focusedhts reserved
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need of significant improvement.
Identifying Binding Hotspots
Hotspots were originally identified as residues at a PPI interface
that contribute significantly to the binding affinity, such that their
mutation to alanine leads to a significant reduction in binding af-
finity (Bogan and Thorn, 1998; Clackson and Wells, 1995). The
term has also been used to refer to clusters of such residues,
which we refer to here as protein surface hotspots. The term
hotspot has also been identified with a site on a protein that
has high propensity for ligand binding, and we refer to these
sites as ligand binding hotspots. The determinants that underlie
both phenomena are very similar, and here we use the term hot-
spot to overarch the two (Zerbe et al., 2012). There are a num-
ber of methods for identifying hotspot regions at protein sur-
faces (Villoutreix et al., 2014), commonly assessed by their
ability to recapitulate experimental data from sources such as
the ASEdb alanine scanning energetics database (Thorn and
Bogan, 2001), the BID (Binding Interface Database) (Fischer
et al., 2003), and the HotSprint database (Guney et al., 2008).
The first class of methods is empirical and correlates experi-
mental data with surface properties such as protein curvature,
electrostatic potential, or hydrophobicity. This approach has
generated software that accurately predicts protein surface hot-
spots, such as HotPoint (Tuncbag et al., 2009), and software
that accurately predicts ligand binding hotspots, such as Site-
Map (Halgren, 2009). The second class of methods uses explicit
computational alanine scanning, which predicts changes in
binding free energy upon mutation to alanine. This can be
achieved by free energy methods such as molecular me-
chanics/generalized Born surface area (Gohlke et al., 2003),
free energy perturbation (FEP), and thermodynamic integration
(TI) (Moreira et al., 2007). Recent studies suggest that the
MM-GBSA method yields accurate results that are comparable
or better than more computationally intensive TI calculations
(Martins et al., 2013). Other studies suggest that Poisson Boltz-
mann implicit solvation is more accurate than generalized Born
implicit solvation in the context of computational alanine scan-
ning (Bradshaw et al., 2011).
The third class of methods involves physics-based analysis of
ligand binding hotspots. This includes analysis of probe frag-
ments (Brenke et al., 2009), which suggest where larger ligands
will bind, but also water molecules (Haider and Huggins, 2013).
Hydrophobic desolvation is a key driver of PPIs, and binding hot-
spots are often found in hydrophobic regions. For this reason, it
is useful to consider water at PPI interfaces and also its displace-
ment by other small molecules (Landon et al., 2007). Solvation
has also been explicitly modeled using FEP, TI, and inhomoge-
neous fluid solvation theory (IFST) (Huggins and Payne, 2013;
Li and Lazaridis, 2006). Schrodinger’s WaterMap is a commer-
cially available IFST software package that is widely used in
the pharmaceutical industry to understand SAR, and has been
used to understand the determinants of affinity in the PPIs of
PLK1 (Huggins et al., 2010) and identify ligand binding hotspots
on the FKBP12 protein (Beuming et al., 2012). In this study, pre-
dicted hotspots correlate positively with a high hit rate in NMR
screening of fragments. A number of web server tools for hotspot
prediction are now available in all three classes, including Ro-
betta (Kim et al., 2004), DrugScorePPI (Kru¨ger and Gohlke,Chemistry & Bi2010), and HotPoint (Tuncbag et al., 2010). A list of such tools
can be found at http://www.vls3d.com. Within any of these ap-
proaches, it is clear that protein flexibility must be modeled to
yield a generally applicable tool for identifying binding hotspots
(Lexa and Carlson, 2010).
Modeling Molecular Flexibility
As discussed above, protein flexibility is a very important feature
of molecular recognition for PPIs (Brown and Hajduk, 2006). This
is true for interactions between native partners and for small-
molecule inhibitors. This means that conformational flexibility
must be considered explicitly for computational methods to be
effective in modeling a broad range of PPIs (see the section on
Structural Plasticity). One approach that has proved useful in
molecular docking is the use of predefined structural ensembles.
In this case, an ensemble of multiple protein structures is used
for analysis rather than one single protein structure. A recent re-
view notes that it leads to better performance than the worst sin-
gle protein structure in almost all cases (Korb et al., 2012). Thus,
approaches based on structural ensembles are preferred
because the virtual screening performance of a single protein
structure for a given ligand is unknown. In terms of selecting
the ensemble, protein structures can be derived from experi-
mental techniques such as NMR and X-ray crystallography
(Damm and Carlson, 2007) or from computational techniques
such as molecular dynamics (MD) (Cheng et al., 2008). Crucially,
it is clear that the selection of the ensemble is a critical determi-
nant of performance for molecular docking (Korb et al., 2012),
druggability assessments (Brown and Hajduk, 2006), and hot-
spot identification (Metz et al., 2012). While there have been ad-
vances in modeling induced fit effects, major difficulties remain
in modeling major domain motions (Wells and McClendon,
2007). The two key aspects of effective computational modeling
are comprehensive sampling techniques and accurate estima-
tion of free energy. Modeling large domain motion requires
both of these aspects. Thus, accurately computing the energetic
cost of protein rearrangement is achievable using FEP methods,
but only in cases where the ligand binding mode is known (Wang
et al., 2013). Similarly, replica exchange MD (REMD) (Miyashita
et al., 2009) and enveloping distribution sampling (Riniker
et al., 2011) have both been successfully applied to model large
domain motion, but extending these methods to virtual
screening and combinatorial molecular design is beyond the
scope of current computational power. However, computational
methods have shown promise in identifying transient pockets at
PPIs. These cryptic pockets are not present in the apo structure
of the protein, but are revealed upon ligand binding. Importantly,
such pockets are not an uncommon feature (Bernini et al., 2014;
Foster et al., 2012; Schames et al., 2004; Tan et al., 2012) and are
promising targets for therapeutic intervention (Johnson and Kar-
anicolas, 2013). Because these pockets are not present in the
majority of structures that make up the conformational ensemble
in the apo state, they can be difficult to identify using conven-
tional MD simulations. For this reason, methods that are based
on probe molecules, such as MixMD (Lexa and Carlson, 2013)
and SILCS (Foster et al., 2012; Raman et al., 2011), have proved
more effective. One additional factor is the interplay of the de-
grees of freedom for the water and protein, which can lead to
enthalpy/entropy compensation and confound commonly
applied computational approaches (Breiten et al., 2013). This isology 22, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 697
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wer of computational methods.
Virtual Screening
Virtual screening (VS) is often used in an attempt to enrich com-
pound libraries for molecules with an increased likelihood of
hitting a particular target. The two main methods used for VS
are structure-based and ligand-based screening (Ripphausen
et al., 2010). Structure-based screening is commonly performed
using one of three techniques. Molecular docking uses an atom-
istic description to compute the ligand-protein interactions,
pharmacophore screening matches the features of the ligand
to those of the binding site, and shape-based screening as-
sesses the geometric fit between the ligand and the binding
site. Ligand-based screening is used to identify new hit mole-
cules using information about existing hit molecules. There are
a number of pitfalls associated with the use of VS (Scior et al.,
2012), and these should be understood before applying it. It
can also be useful to utilize an ensemble of protein structures
(see the section onModelingMolecular Flexibility) in all these ap-
proaches (Fan et al., 2009; Totrov and Abagyan, 2008). One
might expect that VS would find greater utility in identifying PPI
inhibitors, due to the lower experimental hit rates and require-
ment to test larger and more complex molecules. However, the
majority of VS methods have been optimized for buried active
sites, and it is not clear that these will translate to calculations
at protein surfaces. Despite this, existing and purpose-built VS
approaches have shown promise (Fernandez-Recio et al.,
2004; Rouhana et al., 2013; Villoutreix et al., 2014). For example,
a ‘‘fuzzy’’ pharmacophore model combined with GOLD docking
(Jones et al., 1995) was used to identify interferon-a inhibitors
(Geppert et al., 2012), and consensus scoring using DOCK4 (Ew-
ing and Kuntz, 1997) was used to identify STAT3 inhibitors (Mat-
suno et al., 2010). In addition, pharmacophore tools based on
key anchor residues between PPI partners has been used to
identify inhibitors of the p53-MDM2 interaction (Koes et al.,
2012). Utilizing information from native interactions is likely to
be a key enabling step in the efficient design of PPI inhibitors.
Conclusions and Future Perspectives
There are a number of reasons why developing therapeutics to
target PPIs is a challenging process. In general, high-affinity pro-
tein-ligand binding is a driver of drug efficacy and is one of the
key goals in early-stage drug discovery. This high-affinity binding
is derived from close contact at the protein-ligand interface, and
at protein surfaces a significant proportion of the ligand is
exposed to solvent rather than in contact with the protein.
Thus, for a given level of binding affinity, PPI inhibitors tend to
be larger than inhibitors of buried binding sites. An increase in
size brings with it a greater risk of PK/PD liabilities that may
lead to drug failure. For this reason, PPI targets are considered
to be inherently less druggable than traditional targets. Addi-
tional difficulties arise from the confounding effect of surface
flexibility on structure-based drug design, and the challenges
of target selection due to the complexity of cellular networks.
However, PPI inhibitors hold great promise for the generation
of selective therapeutics for a variety of diseases if these diffi-
culties can be overcome. For this reason, great efforts have
been focused on devising novel chemical, biological, and
computational tools to aid in the process of developing PPI inhib-698 Chemistry & Biology 22, June 18, 2015 ª2015 Elsevier Ltd All rigitors. These tools are described in this review. In the future, we
see four key areas where advances in our understanding and in-
creases in the utility of computational techniques will further the
development of PPI inhibitors.
To date, PPIs have been targeted only sporadically with small
molecules, at least partly because existing RNAi technologies
are unable to associate specific PPIs with specific cellular phe-
notypes. Indeed, knockdown of candidate targets with RNAi
can often be uninformative, due to the simultaneous depletion
of beneficial as well as disease-associated protein interfaces.
Therefore, since the current state of the art for target identifica-
tion and validation is unsuitable for the identification of protein in-
terfaces, it is not surprising that few PPIs have been validated as
prospective targets using current tools. The problem of target
selection is an area where computational approaches to sys-
tems biology hold great promise (Kreeger and Lauffenburger,
2010). However, it will be vital to use computational models to
design experiments that are able to verify which protein targets
within a cellular network are most amenable to selective interfer-
ence to achieve the desired goal. Molecular biology is now an
immensely powerful field, but probing a complex system re-
quires careful study. This is an area where academic work can
contribute significantly to industrial progress. Understanding
particular cellular pathways and the PPIs involved can take
many years of work, but is a fruitful field for publication during
this time and can be exploited at the conclusion for commercial
purposes. The development of methods for the high-throughput
identification of druggable PPIs for a given pathway or pheno-
type would significantly expedite the process of drug discovery
against PPIs.
Academic research can also prove useful in the related pro-
cess of validating difficult drug targets such as PPIs. Pharma-
ceutical companies are naturally wary of the risks associated
with developing PPI inhibitors, and this is particularly true for un-
validated protein targets. The process of target validation can be
a lengthy process and requires a coordinated multidisciplinary
approach. For this reason, large initiatives such as the NIH
Accelerating Medicines Partnership, the Wellcome Trust Seed-
ing Drug Discovery funding, and the UK Technology Strategy
Board Biomedical Catalyst funding will be a key part of target
validation in the future. Publicly available data on the therapeutic
potential of targeting all relevant proteins in the human genome
would greatly enhance decision-making processes. However,
the breadth and heterogeneity of genetic data will require clev-
erly designed and well-maintained databases.
Publicly available data will also enable the design of effective
screening libraries for PPIs. The results of many PPI screens
with many libraries, including those where no leads were ulti-
mately identified, will provide valuable information on whether
particular libraries will fare well against PPIs, and whether partic-
ular PPIs may not be amenable to small-molecule inhibition.
Unfortunately, both academia and industry are reluctant to pub-
lish negative results, and positive results are often delayed due to
patent issues. Even when screens with positive results are pub-
lished, a readerwill rarely haveaccess toall compoundstructures
and associated activities. Only with a complete dataset can a
comprehensive analysis be carried out.Weenvisage that the cur-
rent drive for ‘‘big data’’ will help to separate druggable and un-
druggable PPIs and validate effective screening libraries for PPIs.hts reserved
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mental data may not prove as fruitful is the identification of
cryptic binding pockets at protein surfaces. Such pockets are
often druggable but are not identified by X-ray crystallography
of the apo protein structure. Brute force experimental ap-
proaches using HTS or arrayed library synthesis can work but
the vast size of chemical space means that such approaches
will commonly fail. Conversely, computational methods can
search the conformational space of the protein surface and iden-
tify the presence or absence of druggable pockets. The two bar-
riers to achieving this are the two main issues that have always
existed in computational drug discovery: sampling and scoring
(Schneider, 2012). Significant progress has already been made
in circumventing the first of these hurdles, using enhanced sam-
pling such as REMD and long-timescale calculations with multi-
ple processors. It is the second barrier that is the current chal-
lenge, with many classical force fields failing to generate
accurate protein-structural ensembles (Beauchamp et al.,
2012) and quantum mechanical approaches still too computa-
tionally expensive for the analysis of such large systems. Further
increases in computing power will allow better models to be
applied to larger systems, and allow druggable cryptic binding
pockets to be identified from crystallographic apo structures.
These approaches will also improve our understanding of allo-
steric modulation of PPIs.
In summary, the development of effective therapeutics from
PPI inhibitors will be improved by the widespread dissemination
of relevant data from large multidisciplinary projects, the effec-
tive use of such data, and the exploitation of increased
computing power to accurately model ensembles of protein
structures. Science is already moving in these directions, but
academia and industry will need to work together in order to
turn this movement into positive outcomes for society.
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